

Metástases Ósseas e/ou Hipercalcemia Maligna

Denosumabe: 120 mg SC D1 a cada 30 dias

Ref. (1)

OU

Pamidronato: 90mg IV D1 a cada 28 dias

Ref. (2)

OU

Ácido zoledrônico: 4 mg IV D1 a cada 21 a 28 dias

Ref. (3)

1. Stopeck Alison T., Lipton Allan, Body Jean-Jacques, *et al.* Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol.* 2010; 28: 5132-5139.
2. Berenson JR, Hillner BE, Kyle RA, *et al.* American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. *J Clin Oncol* 2002 Sep 1;20(17): 3719-36.
3. Migliorati Cesar A, Siegel Michael A, Elting Linda S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. *Lancet Oncol.* 2006; 7: 508-514.